The HOYA MiYOSMART was the first of the new generation of myopia control spectacle lenses, with evidence for slowing myopia progression by at least half. Learn more about efficacy, the lens design, visual outcomes and more.
This prospective observational study found that DIMS spectacle lenses, atropine 0.01% and the combination of the two all showed robust efficacy for myopia control in European children. The combination treatment showed slightly better refractive control than the mono-therapies, but axial length growth was similar in all treatment groups.
The first year data from the ongoing CYPRESS randomized clinical trial show that Diffusion Optics Technology (DOT) spectacle lenses can regulate contrast signals across the retina to reduce myopia progression in children aged 6-10 years, and are safe and effective to wear.
The SightGlass DOT 0.2 lens presents a new theory in myopia control, with clinical trial evidence of efficacy in children from 6 to 10 years of age. Diffusion Optics Technology (DOT) incorporates microdots to modulate retinal contrast; it does not employ defocus as for other optical treatments. Learn more here.
The contrast theory in myopia development and control is based on links between retinal cone expressions, genetics and myopia. This is distinct from peripheral defocus and simultaneous defocus theories and underpins the new SightGlass DOT 0.2 spectacle lens for myopia control. Learn more here.
A dose-response is where an increasing amount of a medication or intervention is correlated with a better clinical outcome. When it comes to myopia control, we investigate the evidence for a dose-response with spectacle, contact lens, atropine and outdoor time interventions.
Our Q&A format explores new technologies, products and research with experts. In this interview, Dr Sherman Tung, optometrist from Canada, shares his experience with The SightGlass Vision DOT 0.2 Lens in his practice, from prescribing to parent explanations and clinical outcomes.
Peripheral vision function and reading speed were unaffected by highly aspherical (HAL) and slightly aspherical lenslet (SAL) spectacle lens designs compared to single vision lenses. Low contrast acuity was slightly reduced through the lenslet zone.
In this case, a colleague has his first experience with the new Essilor Stellest spectacle lens for childhood myopia, with discussion including when to change the prescription and when to stop treatment.
This study evaluated the visual performance and optical quality of three lenslet design spectacle lenses. While all degraded visual performance in some capacity, the concentric design (highly and slightly aspherical) lenses generally had a significantly lower impact on both acuity and contrast than honeycomb configuration (HC).
